Prostate Cancer, Sleep, and Cognition
The Impact of Androgen Deprivation Therapy On Sleep And Cognition In Men With Prostate Cancer
** CLOSED TO RECRUITMENT**
This study is examining the effect of androgen deprivation therapy on sleep and cognitive functioning in men with prostate cancer.
This research is important because it will help us to understand how sleep before and during prostate cancer treatment might influence the development of other side effects such as difficulty remembering things and paying attention. This information may be used to help develop targeted prevention and/or intervention programs to help other men in the future.
Study Findings
Click below to read more about the findings of this study:
1. Androgen Deprivation Therapy and Radiation for Prostate Cancer—Cognitive Impairment, Sleep, Symptom Burden: A Prospective Study
Published Abstracts
SLEEP 2019 - 0825 The Effect of Androgen Deprivation Therapy on Insomnia Symptoms, Fatigue, Mood, and Hot Flashes in Men with Non-Metastatic Prostate Cancer
SLEEP 2019 - 0826 A Comparison of Pre-Treatment Sleep and Symptom Profiles in Age-Matched Breast and Prostate Cancer Patients
SLEEP 2019 - 0829 Exploring Insomnia as a Factor Contributing to Cognitive Difficulties in Newly Diagnosed Men with Prostate Cancer
IPOS 2019 - 231 | A Prospective Analysis of Insomnia and Subjective Cognitive Impairment in Men with Prostate Cancer on Androgen Deprivation Therapy
Prostate Cancer Foundation 27th Scientific Retreat - Cognitive Impairment and Symptom Change in the First 12 Months of Treatment for Prostate Cancer
CAPO 2020 - 43 | A Comparison of Sleep and Symptom Profiles in Age-Matched Breast and Prostate Cancer Patients One-Year Post-Diagnosis
Investigators
Primary Investigator:
Sheila N. Garland, PhD
(Department of Psychology, Faculty of Science and Division of Oncology, Faculty of Medicine)
Co-Investigator:
John Thoms, MD, FRCPC
(Division of Oncology, Faculty of Medicine)
Students:
Kayla Wall, BSc,
Samantha Scurrey, BA,
Nicole Rodriguez, BSc
Supported by grants from the Division of Oncology
at Memorial University and the Beatrice Hunter
Cancer Research Institute (BHCRI)
